Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.

A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.

Japan's latest batch of new drug approvals includes the country's second CAR-T therapy, along with multiple oncology drugs and a novel migraine treatments, which should all reach the market in the next few months following reimbursement price listing. 

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.